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Introduction
Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal 
dominant neuromuscular disorder with a prevalence of 1:20,000 
to 1:15,000 worldwide (1). The major form of FSHD (FSHD1A, 
OMIM #158900) is associated with a reduction of subtelomeric 
repeats (D4Z4) on the long arm of chromosome 4 (4q35). The nor-
mal polymorphic allele ranges from 11 to 100 D4Z4 units, whereas 
the pathologic one ranges from 1 to 10 units (1).
Clinical symptoms of FSHD range from mild (weakness of 
limited muscles) to severe (wheelchair dependence), with most of 
the affected individuals showing symptoms by age 20 (1). A subset 
of individuals (21%) do not even show clinical signs (asymptomat-
ic carriers) or are minimally affected. Extreme variability is pres-
ent even in members of the same family carrying the same repeat 
array size, especially when the fragment size is in the higher range 
(2).The interfamilial variability of clinical symptoms is in part 
explained by the extent of D4Z4 contraction; indeed, a roughly 
inverse correlation exists between the number of residual D4Z4 
units and the severity of clinical phenotype. Intrafamilial variabil-
ity is still largely unexplained. Sex is one of the factors affecting 
sensitivity to the disease, with females being less severely affected 
than males and presenting a higher proportion of asymptomatic 
carriers, especially in the presence of a mild/long allele (3–5). The 
reduced correlation between the fragment size and age-correct-
ed clinical severity score in female compared with male patients 
suggests the existence of specific disease modifiers in women 
(6). Additionally, no correlation has been found between sex and 
severity of phenotype in infantile FSHD patients (7). Although 
these patients usually carry short repeat arrays associated with 
high disease penetrance (8), a possible role for adult sex-related 
factors in the clinical presentation of the disease can be hypothe-
sized. Furthermore, some studies have reported a persistent wors-
ening of symptoms after childbirth in a subset of female FSHD 
patients (9–11). Since a strong drop of hormone levels character-
izes this condition, a plausible hypothesis is that female hormones 
and possibly estrogens may be involved in FSHD disease (12).
At the cellular level, FSHD myoblasts are characterized 
by (a) impaired differentiation with reduced fusion index and 
altered myotube structure; (b) increased sensitivity to oxidative 
stress; and (c) reduced viability of differentiated myotubes due to 
increased cell death and/or increased atrophy (13). The molecu-
lar mechanisms that underlie these phenomena are incomplete-
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Results
Estrogens enhance in vitro differentiation of FSHD-derived myoblasts. 
To study the activity of estrogens in FSHD, we used myoblasts 
isolated from affected patients compared with myoblasts from 
healthy individuals. Four myoblast cell cultures were obtained 
from patients affected by FSHD1, 2 females (hereafter FSHD#1 
and FSHD#2) and 2 males (FSHD#3 and FSHD#4). Control myo-
blast cell cultures were derived from 1 healthy male (CTL#1) and 
2 females (CTL#2 and CTL#3). Features related to these individ-
uals are reported in Supplemental Table 1 (supplemental materi-
al available online with this article; doi:10.1172/JCI89401DS1). 
Given the short in vitro life span of FSHD primary cells, control 
and FSHD myoblasts were immortalized by retroviral infection 
with the CDK4-R24C variant and hTERT expression vectors (23). 
Analysis of cell positivity to the myoblast lineage marker desmin 
revealed that all immortalized cell cultures maintained 90% or 
more cells positive for desmin, similar to primary cells (Supple-
mental Figure 1, A and B), indicating that the immortalization 
procedure did not alter myoblast phenotype. As a control, primary 
human fibroblasts were entirely negative to this marker (Supple-
mental Figure 1B). Moreover, the immortalization did not prevent 
the differentiation of myoblasts, as indicated by the positivity to 
the marker of terminal differentiation, myosin heavy chain (MHC) 
(Supplemental Figure 1C).
Isolated FSHD myoblasts are characterized by altered differen-
tiation and fusion in vitro (24–27). To ascertain whether estrogens 
play a protective role in FSHD, we analyzed their ability to improve 
FSHD muscle differentiation. To this aim, immortalized myoblasts 
ly defined. The current molecular pathogenetic model of FSHD1 
proposes that contraction of the D4Z4 array is accompanied by 
DNA hypomethylation (14–16) that leads to a decreased heteroch-
romatinization of the region. In turn, this leads to the transcrip-
tion of usually repressed genes. Among these, double homeobox 4 
(DUX4), mainly expressed by the last D4Z4 unit, is the best FSHD 
candidate gene. DUX4 is a transcription factor that regulates 
genes involved in stem cell and germline development (17). Its 
aberrant expression in myoblasts alters factors involved in muscle 
differentiation, oxidative stress homeostasis, and muscle atrophy 
in addition to immune response and RNA surveillance, therefore 
recapitulating the key features of FSHD myopathy (18). At present, 
there are no studies, to our knowledge, reporting estrogen activity 
toward DUX4 levels and/or function.
Estrogen activity is mediated mainly by 2 nuclear receptors: 
estrogen receptor α (ERα) and estrogen receptor β (ERβ). The 
characterization of the 2 receptors in the human muscle has pro-
vided conflicting results. Indeed, the mRNAs of the ERα and ERβ 
genes (ESR1 and ESR2, respectively) have been reported in human 
muscle (19, 20). However, the presence of ERα protein has not 
been definitely proved (20, 21), raising the possibility that ESR1 
is not expressed in human muscle cells and that the mRNA sig-
nal derives from environmental cells (i.e., endothelial cells, fibro-
blasts). Conversely, the expression of ERβ in human myoblasts has 
been shown by immunohistochemistry (IHC) (22).
In this work, we investigated the effect of estrogens in FSHD 
and demonstrated that estrogens improve the differentiation prop-
erties of FSHD-derived myoblasts by antagonizing DUX4 activity.
Figure 1. E2 enhances differentiation of immortalized FSHD myoblasts. (A–L) Representative photographs of MHC immunostaining (red) of myoblasts 
from indicated FSHD patients and healthy individuals after 7 days of culture in differentiation medium in the absence or presence of 10−8 M E2. Nuclei were 
counterstained with DAPI (blue). Scale bar: 75 μm. (M) Percentage of MHC+ cells treated as in A–L. Percentage MHC+ cells = MHC+ nuclei/total number of 
nuclei. Pink bars represent female, blue bars male myoblasts. (N) Fusion index in the same fields analyzed in M. Fusion index = percentage of nuclei in 
MHC + myotube/number of total nuclei, where a myotube is a MHC+ cell with 3 nuclei. Data in M and N represent the mean ± SD of 3 independent exper-
iments, except 2 experiments are represented for FSHD#2 and CTLs. For each experiment, 4 fields/condition were counted (n = 12 for FSHD#1, FSHD#3, 
and FSHD#4; n = 8 for FSHD#2, CTL#1, and CTL#2). ***P < 0.001; **P < 0.01; *P < 0.05, 2-tailed Student’s t test. The complete set of fields evaluated in 
this experiment is reported in Supplemental Figure 6.
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replaced every other day, and after 1 week, cells were immuno-
stained for MHC (Figure 1, A–L). The overall differentiation of the 
immortalized FSHD myoblasts was decreased compared with that 
of healthy controls (compare Figure 1, A–H to I–L, and Figure 1, M 
and N). Interestingly, E2 increased the number of differentiated 
cells in comparison with cells treated with vehicle (etOH) inde-
pendently of the sex of patients providing FSHD myoblasts and the 
were differentiated in the presence or absence of 17β- estradiol 
(E2), the predominant hormone in terms of estrogenic activity. 
Cells were plated at high confluence (>90%, 300 cells/mm2) and 
grown for 16 hours in medium deprived of estrogens and estro-
gen-like substances. Afterward, cultures were switched to differen-
tiation medium deprived of estrogen and estrogen-like substances 
(hereafter Diff) in the presence or absence of E2. The medium was 
Figure 2. E2 enhances differentiation of primary FSHD-isolated myoblasts. (A) Percentage of MHC+ myoblasts from indicated healthy individuals and 
FSHD patients after 7 days of culture in differentiation medium in the absence or presence of 10–8 M E2. Percentage of MHC
+ cells = MHC+ nuclei/total 
number of nuclei. Pink bars represent female, blue bars male myoblasts. (B) Fusion index in the same fields evaluated in A. Fusion index = percentage 
of nuclei in MHC + myotube/number of total nuclei, where a myotube is an MHC+ cell with 3 or more nuclei. Data in A and B represent the mean ± 
SD of 2 independent experiments, but 1 experiment is represented for CTL#1, FSHD#2, and FSHD#3. For each experiment, 8 fields/condition were 
counted. (n = 8 for CTL#1, FSHD#2, and FSHD#3; n = 16 for all other myoblast cell lines). ***P < 0.001; **P < 0.01; *P < 0.05, 2-tailed Student’s t test. 
A subset of 8 fields/condition for all FSHD and CTL#14 and 03U myoblasts evaluated in this experiment is reported in Supplemental Figure 6.
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cence. In the absence of E2, DUX4-V5 overexpression led to a 
strong decrease in the number of MHC-positive cells, support-
ing its activity in impairing muscle differentiation (Figure 3, A 
and B, and refs. 24, 32). Of note, the presence of E2 antagonized 
this effect and was able to efficiently recover the differentiation 
impairment caused by DUX4 whereas it did not affect the differ-
entiation of cells transfected with control vector (Figure 3, A and 
B). Western blot of myotubes after 1 and 3 days of differentiation 
confirmed the continued expression of DUX4-V5, substantially 
not altered by E2 (Figure 3C), suggesting that estrogens do not 
function by altering the protein levels of DUX4. Since it has been 
reported that DUX4 is degraded through the proteasome system 
(25), to confirm further that estrogens do not affect DUX4 pro-
tein stability, we analyzed DUX4 in the presence or absence of 
proteasome inhibitor MG132. Under the conditions used in our 
experiments, MG132 did not stabilize and rather decreased the 
levels of DUX4-V5. Importantly, E2 did not further alter these 
levels (Figure 3D), confirming that E2 does not modify DUX4-V5 
levels. As a control, the levels of MDM2 and p21, 2 well-known 
targets of proteasome activity, were highly increased by MG132. 
To get more insights into the activity of E2 toward DUX4 and 
exclude any interference of the epitope tag, the myoblast dif-
ferentiation experiments were repeated by expressing DUX4 
in frame with the mCherry protein at the N terminus (hereafter 
Cherry-DUX4). In the absence of E2, the double fluorescence 
of the mCherry and the MHC signals confirmed the substantial 
reduction of MHC-positive cells in DUX4-expressing cells (Fig-
ure 3E), confirming the impairment of myoblast differentiation 
by DUX4. Once again, E2 significantly improved the differenti-
ation properties of myoblasts (Figure 3, E and F). Overall, these 
data indicate the ability of estrogens to antagonize DUX4-medi-
ated impaired muscle differentiation.
Overexpression of DUX4 has been associated with cell death 
in murine and human muscle cells (31, 33, 34). To exclude that E2 is 
acting as a prosurvival factor, the Cherry-DUX4 transfected cells 
were analyzed for the expression of the apoptosis marker annexin 
V. The number of the double–annexin V/mCherry–positive cells 
was indeed increased in Cherry-DUX4 compared with mCher-
ry-transfected cells, independently of cell growth conditions, con-
firming the toxicity of overexpressed DUX4. However, this frac-
tion was not significantly altered by E2 treatment (Supplemental 
Figure 3), thus excluding a prosurvival effect of E2 and confirming 
its ability to counteract specifically the differentiation impairment 
caused by DUX4.
ERβ mediates estrogen-enhanced differentiation. E2 is the natural 
ligand of ERα and ERβ. To understand which receptor underlies 
the E2 activity in FSHD myoblasts, ERα and ERβ expression were 
analyzed in control and FSHD myoblasts. Quantification of mRNA 
for ESR1 and ESR2 genes showed that the levels of ESR1 were very 
low in all myoblast populations as compared with the levels of 
ERα-positive breast cell line MCF7, set to 1 (fold of reduction ≥ 80) 
and were comparable to the levels of ERα-negative MDA-MB-231 
cells (ref. 35 and Figure 4A). Accordingly, no detectable levels of 
ERα protein by Western blot were observed in primary cells (Sup-
plemental Figure 4A), in agreement with previous data (20). Since 
ERα mainly mediates proliferation, these data well conform with 
the lack of E2 proliferative activity in these cells. Conversely, the 
fragment length (Figure 1M and Supplemental Table 1). Particular-
ly, a significant increase in the number of multinucleated myotubes 
was evident in all FSHD cell cultures (Figure 1N). Importantly, in 
control myoblasts, no significant change was evident, indicating 
that the observed effects are specific for FSHD myoblasts (Figure 1, 
I–N). The average density of nuclei/mm2 in the FSHD samples (243 
± 48) was reduced compared with that of controls (316 ± 8), but was 
not significantly different between etOH and E2 (FSHD, 228 ± 36 
vs. 258 ± 60; CTL, 319 ± 10 vs. 314 ± 8).
To ascertain that these effects are not related to the immor-
talization procedure and to confirm these data in additional cell 
lines, previous differentiation conditions were applied to prima-
ry FSHD and control myoblasts isolated from 2 different centers. 
Compared with the previous immortalized cell lines, primary 
FSHD myoblasts showed a distribution of differentiation and 
fusion index closer to that of healthy individuals (Figure 2, A and 
B). Particularly, primary FSHD#2, FSHD#3, and FSHD#4 myo-
blasts showed increased differentiation properties compared with 
their immortalized counterparts (see Figure 1, M and N), suggest-
ing that the immortalization procedure reduces FSHD differenti-
ation potential. Importantly, E2 treatment significantly improved 
differentiation capabilities of all primary FSHD myoblasts while 
not affecting those of controls (Figure 2, A and B), thus confirming 
previous results and highlighting a particular sensitivity of FSHD 
myoblasts to estrogens. No significant difference was observed 
in the average density of nuclei/mm2 between etOH and E2 treat-
ment of each control or FSHD cell line (Supplemental Figure 2A). 
To conservatively analyze these results and avoid the influence of 
the FSHD-reduced differentiation in the evaluation of the fusion 
index, we also analyzed the percentage of nuclei in myotubes 
related to the number of MHC+ nuclei (corrected fusion index 
[FIcorr]) rather than to the total number. This parameter was still 
significantly enhanced by estrogens in FSHD myoblasts while not 
in control cells (Supplemental Figure 2B).
One of the well-established activities of estrogens is their 
proproliferative/prosurvival action, mainly attributed to ERα (28, 
29). We therefore wondered whether the E2-enhanced differ-
entiation was related to an increased number of differentiating 
cells. Previous data do not indicate a significant difference in the 
final number of etOH- and E2-treated differentiated cells. Fur-
ther time-course analysis of cell growth in different primary and 
immortalized cell lines showed that E2 treatment did not increase 
the number of FSHD and control myoblasts during differentiation 
(Supplemental Figure 2, C–E) or in proliferative conditions (Sup-
plemental Figure 2F). These data exclude that the E2-mediated 
enhanced differentiation of FSHD myoblasts is due to increased 
proliferation, thus supporting a specific activity of these hormones 
toward FSHD myoblasts.
Estrogens antagonize DUX4-mediated impairment of myoblast 
differentiation. The expression of full-length DUX4 is consid-
ered the main pathogenic factor of muscular dystrophy in FSHD 
patients (25, 30). We, therefore, tested whether estrogens spe-
cifically counteract DUX4-mediated activity. Control myoblasts 
were transfected with DUX4 coding sequence in frame with the 
V5 tag at the C-terminal (hereafter DUX4-V5) (31), and after 5 
days of growth in the Diff medium with or without E2, myotube 
formation was verified by analysis of MHC immunofluores-
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FLAG-tagged ERβ (ERβFLAG) as positive control confirmed these 
data (Figure 4, C and D). Of note, E2 decreased the protein levels 
of ERβ both endogenously and exogenously expressed, whereas 
tamoxifen antagonized this reduction (Figure 4D). This decrease 
occurred as a negative feedback when estrogen receptors were 
stimulated by their ligand in estrogen-responsive tissues, whereas 
this phenomenon does not occur in the absence of estrogen-me-
diated transcriptional activity (37). These data, therefore, further 
support the presence of active ERβ in these cells. Overall, these 
data demonstrate that ERβ is E2 sensitive and functioning in these 
cells and suggest its involvement in E2 activity on FSHD myoblast 
levels of ESR2 were comparable to those of the ERβ-positive ovar-
ian cancer cell line A2780 (36), independently of the sex (Figure 
4B), suggesting that ERβ is expressed in all human myoblasts. In 
fact, Western blot confirmed the presence of the protein in pri-
mary FSHD and control myoblasts (Supplemental Figure 4A). To 
ascertain that ERβ is transcriptionally active in these cells, control 
myoblasts were transfected with a luciferase vector whose expres-
sion was driven by estrogen responsive elements (ERE). Treat-
ment with E2 led to a sharp increase in luciferase activity, which 
was counteracted by the addition of tamoxifen, an antagonist 
of estrogen receptor activity (Figure 4C). The overexpression of 
Figure 3. E2 antagonizes DUX4-mediated impairment of myoblast differentiation. (A) Representative photographs of MHC immunostaining (red) in 
control myoblasts transfected with empty vector (mock, upper panels) or DUX4-V5 (lower panels) after 4 days of culture in differentiation medium in the 
absence or presence of E2. Nuclei were counterstained with DAPI (blue). Scale bar: 75 μm. (B) Percentage of MHC+ cells treated as in A. Mean ± SD of 2 
independent experiments is shown. Three different fields for each condition were counted (n = 6). (C) Western blot of the indicated proteins in the lysates 
from myoblasts treated as in A. DUX4-V5 was detected by aV5 antibody. (D) Western blot of the indicated proteins in control myoblasts transfected as in 
A and collected after 72 hours of culture in differentiation medium with or without E2 and with 60 μM MG132 for the last 4 hours. See complete unedited 
blots for C and D in the supplemental material. (E) Representative photographs of MHC immunostaining (green) in control myoblasts transfected with 
Cherry-DUX4 (red) after 3 days of culture in differentiation medium in the absence or presence of E2. Nuclei were counterstained with DAPI (blue). Scale 
bars: 75 μm (upper panels); 25 μm (lower panels). (F) Quantification of double MHC+ Cherry-Dux+ cells. Mean ± SD of 2 independent experiments is shown. 
Four different fields for each condition were counted (n = 8). **P < 0.01; ***P < 0.001, 2-tailed Student’s t test.
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differentiation. To verify this hypothesis, 2 specific ERβ agonists 
were used: diarylpropionitrile (DPN), which has a 70-fold selectiv-
ity over ERα (38), and a natural endogenous ligand of ERβ, 5α-an-
drostane-3β,17β-diol (3β-diol). Of note, both ligands were able to 
recapitulate and even increase the positive effect of E2 on differen-
tiation of immortalized FSHD#1 myoblasts (Figure 4E), both as a 
percentage of MHC-positive cells (Figure 4F) and as a fusion index 
(Figure 4G), whereas cotreatment with tamoxifen antagonized 
the E2 beneficial effect (Figure 4, E–G). Analysis of average nuclei 
numbers in each treatment by Kruskal-Wallis with Bonferroni’s 
correction did not show any significant difference, thus exclud-
ing an evident proliferative activity of these hormones. Further 
time course analysis of cell proliferation of cells treated with the 
most effective ERβ agonist, DPN, did not evidence any alteration 
of this parameter (Supplemental Figure 4B). These data establish 
the ERβ-mediated beneficial activity of estrogens on FSHD myo-
blast differentiation. Retrospective analysis of a limited number 
of female patients who underwent a rapid decline in estrogen lev-
Figure 4. ERl3 mediates estrogen-enhanced differentiation. (A and B) mRNA levels by qRT-PCR of ESR1 (encoding ERα) (A) and ESR2 (encoding ERβ) 
(B) in immortalized cell lines. ESR1 levels in MCF7 (A) and ESR2 levels in A2780 (B) were set to 1 and the levels in myoblast cell lines relatively calculat-
ed. (C) Relative luciferase activity in CTL#1 myoblasts transfected with estrogen-responsive element-luciferase vector (ERE-Luc) and/or ERβFLAG as 
indicated, treated with or without E2 ± tamoxifen. Luminescence signal was normalized to total protein content. Mean ± SD of 2 independent experiments 
performed in triplicate is shown (n = 6). (D) Western blot analysis of endogenous ER and exogenous ERβFLAG (whose position relative to ER is indicated 
by the arrows) in CTL#1 myoblasts treated as indicated. See complete unedited blots in the supplemental material. (E) Representative photographs of 
MHC immunostaining (red) of myoblasts from FSHD#1 patient after 7 days of culture in differentiation medium in the absence or presence of indicated 
treatments. Scale bar: 75 μm. (F and G) Percentages of MHC+ (F) or fusion index (G) of cells treated as in E. Mean ± SD of 3 independent experiments. Four 
different fields for each condition were counted (n = 12). ***P < 0.001, 2-tailed Student’s t test.
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els and/or activity due to early menopause or as a consequence of 
antiestrogenic treatment for breast cancer evidenced a rapid and 
sharp worsening of clinical symptoms during and/or at the end of 
the treatment (Supplemental Clinical Data, Supplemental Table 
2, and Supplemental Figure 5), supporting the existence of a link 
between estrogen and FSHD. In comparison, relatives carrying the 
same pathologic D4Z4 contraction as well as patients diagnosed 
with other types of cancer and undergoing surgery/chemotherapy 
did not show a similar worsening of clinical parameters (Supple-
mental Tables 2 and 3).
Estrogen antagonizes transcriptional induction of DUX4 target 
genes. Previous data show that E2 does not affect the protein lev-
els of exogenous DUX4. To understand the molecular mechanism 
of E2 activity, we analyzed whether E2 interferes with DUX4 tran-
scription. Analysis of endogenous DUX4 in all FSHD myoblasts 
showed a progressive increase of its mRNA during differentiation, 
with a peak of expression around the third day and a decline at 7 
days (Figure 5, A–D). As a control, DUX4 was undetectable in all 
control myoblasts (Figure 5E). These data are in agreement with 
previous data obtained in fetal FSHD myoblasts and confirm a reg-
ulated expression of DUX4 during FSHD muscle differentiation 
(39). The relative increase of DUX4 was independent of sex and 
not correlated with basal levels of DUX4 mRNA or differentiation 
properties of FSHD cell cultures (see Figure 1, M and N). Impor-
tantly, E2 treatment did not reduce levels of DUX4 (Figure 5F), 
suggesting that E2 may interfere with DUX4 activity rather than 
with its expression. Since DUX4 is a transcription factor, we con-
sidered the expression levels of TRIM43 and ZSCAN4, 2 canonical 
DUX4 target genes (17, 40, 41). The expression of these genes was 
highly increased along the differentiation time course (Figure 6, A 
and B) and approximately paralleled the increase of DUX4, sup-
porting their activation by DUX4 during FSHD myoblast differ-
entiation. Consistently, TRIM43 and ZSCAN4 were not similarly 
induced in control samples (Figure 6C). It is noteworthy that anal-
ysis of these transcripts near their maximum point of expression 
(5 days) showed a significant reduction by E2 in FSHD myoblasts, 
but not in control cells (Figure 6, D and E), indicating that E2 is 
able to interfere with DUX4 transcriptional activity. To further 
support these data, TRIM43 and ZSCAN4 mRNAs were analyzed 
in myoblasts overexpressing Cherry-DUX4. In fact, E2 was able to 
strongly reduce the expression of these genes induced by DUX4, 
whereas it was ineffective in control cells transfected with mCher-
ry vector (Figure 7, A and B). Overall, these data demonstrate that 
E2 impairs DUX4 transcriptional activity. To obtain further insight 
into the molecular mechanism that underlies this phenomenon, 
we analyzed the occupancy of DUX4 on the promoter of its tar-
get, ZSCAN4. Immunoprecipitation of Cherry-DUX4 efficiently 
and specifically coimmunoprecipitated the DNA at the levels of 
the ZSCAN4 promoter (Figure 7C). Of note, E2 strongly reduced 
the levels of coimmunoprecipitated ZSCAN4 promoter, sug-
gesting that estrogen indeed antagonizes DUX4 binding to the 
chromatin, thus reinforcing previous data (Figure 7C). As a fur-
ther indication, trimethylated lysine 4 of histone 3 (H3[Lys4]), a 
marker of transcriptional activation, showed a striking reduction 
of chromatin occupancy on the ZSCAN4 promoter in the presence 
of E2 treatment. Conversely, the levels of an unrelated gene, the 
protooncogene MDM2, were not affected by E2, indicating the 
specific activity of the hormone toward DUX4 targets. To confirm 
Figure 5. DUX4 levels increase during 
differentiation and are not affected 
by estrogens. (A–D) DUX4 mRNA 
levels by qRT-PCR in immortalized 
myoblasts derived from indicated 
patients, cultured in differentiation 
medium without estrogens at the 
indicated time points. The mRNA 
levels at the starting point of differ-
entiation were set to 1. Mean ± SD of 2 
independent experiments is shown. All 
samples were normalized to GAPDH. 
(E) DUX4 mRNA levels by qRT-PCR in 
proliferating immortalized myoblasts 
derived from indicated FSHD patients 
and healthy individuals. The mRNA 
levels of FSHD#1 were arbitrarily set 
to 1. Data derive from 2 independent 
experiments. (F) Fold change of DUX4 
mRNA levels upon E2 treatment at 
the indicated time points of differen-
tiation. The mRNA levels upon etOH 
treatment at each time point were set 
to 1. Mean ± SD of data from 4 FSHD 
patients is shown.
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Pathophysiology of FSHD myoblasts has been associated with 
the expression of PITX1 and of atrogin-1 (also known as FBX032), 
2 genes involved in muscle impairment and atrophy and whose 
transcription has been reported to be increased by DUX4 (33, 42, 
43). To confirm the function of E2 in FSHD muscle impairment 
and DUX4 activity, the expression levels of these 2 genes were 
these data in FSHD myoblasts, endogenous DUX4 or H3(Lys4) 
was immunoprecipitated using FSHD#4 cells. In this case too, E2 
strongly reduced the levels of the coimmunoprecipitated ZSCAN4 
promoter, but did not reduce coimmunoprecipitation of a control 
gene, MDM2 (Figure 7D), confirming the ability of the hormone to 
reduce the transcriptional function of endogenous DUX4.
Figure 6. Estrogens antagonize induction of DUX4 targets. (A and B) mRNA levels by qRT-PCR of TRIM43 (A) and ZSCAN4 (B) in immortalized myoblasts from 
indicated patients, cultured in differentiation medium without estrogens at the indicated time points. The mRNA levels of each gene in proliferating myoblasts 
from CTL#1 (time point 0 [T0]) were arbitrarily set to 1. All samples were normalized to GAPDH. (C) mRNA levels by qRT-PCR of TRIM43 and ZSCAN4 in immor-
talized myoblasts derived from healthy individuals grown as in A and B. The mRNA levels at the time point 0 were set to 1. (A–C) Mean ± SD of 2 independent 
experiments is shown. (D and E) Fold reduction of TRIM43 (D) and ZSCAN4 (E) levels in FSHD and CTL myoblasts collected after 5 days of culture in differentia-
tion medium in the absence (etOH) or presence of E2. The mRNA levels upon etOH treatment in FSHD cells were set to 1. ***P < 0.001, 1-sample t test.
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the DUX4 expression vector used (Figure 9, C and D). Immu-
nofluorescence also confirmed the cytoplasmic localization of 
DUX4 in proliferating myoblasts and its progressively increased 
nuclear localization upon differentiation stimulus (Figure 9, C 
and D). Of importance, analysis of endogenous DUX4 in prima-
ry FSHD3 and FSHD4 myoblasts confirmed its nuclear local-
ization after 4 days of growth in differentiation medium lack-
ing estrogens, whereas the signal appeared diffused in the cell 
or even missing in the nucleus in E2-treated cells (Figure 9E). 
Overall, these data indicate that estrogens antagonize DUX4 
pathogenicity by relocalizing it in the cytoplasm, thereby pro-
viding a molecular mechanism for the ability of these hormones 
to improve FSHD myoblast differentiation.
Discussion
FSHD is an autosomal dominant neuromuscular disease with 
extreme variability in the clinical symptoms. One of the factors 
affecting disease severity is sex, with women being more protect-
ed. Our data demonstrate that estrogens improve the differentia-
tion properties of myoblasts isolated from FSHD individuals. These 
effects are not due to a trophic activity of estrogens on myoblast pro-
analyzed as well. Indeed, PITX1 and atrogin-1 showed the same 
behavior as TRIM43 and ZSCAN4 in FSHD cells (Figure 8, A and 
B), but not in control myoblasts (Figure 8C). Importantly, E2 sig-
nificantly decreased levels of PITX1 and atrogin-1, but it was inef-
fective in control cells (Figure 8, D and E).
Overall, these data demonstrate that estrogens antagonize 
DUX4 transcriptional activity and its differentiation inhibitory 
function and support the protective role of these hormones toward 
FSHD myoblast in in vitro differentiation.
E2 treatment changes DUX4 intracellular localization. Previ-
ous data indicate that E2 reduces DUX4 residency on the pro-
moter of its target. To understand the molecular mechanism, 
we analyzed DUX4 levels in subcellular fractions. Strikingly, 
DUX4-V5 levels were strongly decreased by E2 treatment in the 
chromatin-enriched fraction coincident with its appearance in 
the cytoplasmic fraction (Figure 9, A and B). Interestingly, this 
occurred only in the differentiating cells, whereas E2 was ineffec-
tive in relocalizing DUX4 in proliferating myoblasts (Figure 9A). 
Immunofluorescence experiments confirmed that E2 increased 
cytoplasmic localization of DUX4 upon differentiation, where-
as it was ineffective in proliferating myoblasts independently of 
Figure 7. Estrogens antagonize DUX4 transcriptional activity. (A and B) mRNA levels by qRT-PCR of TRIM43 (A) and ZSCAN4 (B) in control myoblasts over-
expressing mCherry or Cherry-DUX4 and grown in proliferation medium without estrogen (T0) or in differentiation medium without (etOH) or with E2 for the 
indicated time points. All samples were normalized to GAPDH. Mean ± SD of 3 independent experiments is shown (n = 3). ***P < 0.001; *P < 0.05, 2-tailed 
Student’s t test. (C) ChIP qPCR analysis of ZSCAN4 and MDM2 promoters following immunoprecipitation of Cherry-DUX4 (with aDUX4/aCherry antibodies 
mix) or H3K4me3 in control cells overexpressing mock or Cherry-DUX4 and cultured in differentiation medium for 24 hours in the absence or presence of 
E2. Mean ± SD of 2 technical replicates for ZSCAN4 is reported. (D) ChIP qPCR analysis of ZSCAN4 and MDM2 promoters following immunoprecipitation of 
DUX4 (with aDUX4) or H3K4me3 in immortalized FSHD#4 myoblasts after 5 days of differentiation. The results are represented as percentage of input.
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C2C12 and in murine muscles, thus making it necessary to exercise 
caution when comparing data from murine and human tissues. Of 
interest, the ERβ agonist 3β-diol is highly effective in antagoniz-
ing DUX4-mediated activity. Since this hormone is a metabolite 
of dihydrotestosterone (DHT) and is, therefore, present in male 
individuals, its endogenous levels might be an additional factor 
affecting FSHD clinical severity.
liferation or survival. Conversely, estrogens counteract the down-
stream effects of misexpressed DUX4, the gene mostly involved in 
FSHD pathophysiology. Indeed, estrogens antagonize the muscle 
differentiation impairment caused by DUX4 expression.
The beneficial effects of estrogens on FSHD myoblasts are 
mediated by ERβ, whereas ERα is not expressed in these cells. 
Conversely, ERα is expressed in the murine myoblast cell line 
Figure 8. Estrogens antagonize induction of genes involved in FSHD. (A and B) mRNA levels by qRT-PCR of PITX1 (A) and atrogin-1 (B) in immortalized 
myoblasts derived from indicated patients cultured in differentiation medium without estrogens at the indicated time points. The mRNA levels of each 
gene in proliferating myoblasts from CTL#1 (T0) were arbitrarily set to 1. All samples were normalized to GAPDH. (C) mRNA levels by qRT-PCR of PITX1 and 
atrogin-1 in myoblasts from healthy individuals grown as in A and B. The mRNA levels at the time point 0 were set to 1. (A–C) Mean ± SD of 2 independent 
experiments is shown. (D and E) Fold of reduction of PITX1 (D) and atrogin-1 (E) levels in FSHD and control myoblasts collected after 5 days of culture in dif-
ferentiation medium in the absence (etOH) or presence of E2. The mRNA levels upon etOH treatment in FSHD were set to 1. ***P < 0.001, 1-sample t test.
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increased toxicity of this gene in differentiated compared with 
proliferating myoblasts. The mRNA levels of TRIM43, ZSCAN4, 
PITX1, and atrogin-1 increase as well and parallel the increase 
of DUX4 in differentiating myoblasts of FSHD patients, but not 
At the molecular level, our data show that estrogens reduce 
DUX4 transcriptional function during myoblast differentiation. Of 
note, we observed that DUX4 levels and activity increase during 
myotube formation, thus providing a plausible explanation for the 
Figure 9. Estrogens change intracellular localization of DUX4. (A) Western blot analysis of indicated proteins in the cytoplasmic (Cito) or chromatin-en-
riched fraction (chromatin) of immortalized control myoblasts overexpressing DUX4-V5 cultured in differentiation medium for 3 days (Diff. Myo) or in 
proliferation medium (Prol. Myo) in the absence (etOH) or presence of E2. See complete unedited blots in the supplemental material. (B) Quantification of 
DUX levels analyzed as in A. The signal of DUX4 in the absence of E2 was arbitrarily set to 1. Mean ± SD of 3 independent experiments is shown (n = 3).  
**P < 0.01, 1-sample t test. (C) Representative photographs of V5 immunostaining (green) in CTL#1 myoblasts overexpressing DUX-V5 during proliferation 
or differentiation at the indicated time points upon etOH or E2 treatment. Cytoplasm is marked by F-actin signal (red). DAPI counterstains nuclei (blue). 
Scale bar: 25 μm. (D) Percentages of DUX4 nuclear positive myoblasts treated as in C. Mean ± SD of 3 independent experiments is shown. Eight different 
fields/condition were counted (n = 24). ***P < 0.001, 2-tailed Student’s t test. (E) Representative photographs of endogenous DUX4 (green) and MHC (red) 
in primary FSHD#3 and FSHD#4 myoblasts cultured in differentiation medium for 4 days in the presence of etOH (FSHD#4) or E2 (middle panels, FSHD#4; 
lower panels, FSHD#3). DAPI counterstains nuclei (blue). Scale bar: 25 μm.
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Methods
Cell cultures, constructs, transfections, and treatments. Myoblasts 
from healthy controls CTL#1 and CTL#2 were purchased from 
Lonza. Myoblasts from healthy controls 03U, 09U, 12U, and from 
FSHD 03A, 05B, 12A, and 12B were from C. Emerson (University 
of Massachusetts Medical School, Worcester, Massachusetts, USA). 
Myoblasts from healthy controls CTL#3, CTL#10, and CTL#14 and 
from patients FSHD#1, FSHD#2, FSHD#3, FSHD#4, FSHD#10, 
and FSHD#20 were from the Institute of Neurology, Catholic Uni-
versity. None of the patients received either steroids or immuno-
suppressive therapy before biopsies. In each patient, the overall 
clinical severity was assessed using the Clinical Severity Scale 
(CSS), assigning a score of 2 or less when the disease involved only 
facial and scapular muscles and a score of 3 (mildly affected), 3.5 
(moderately affected), or 4–5 (severely affected) when pelvic and 
lower limb muscles were involved (4). Cells were isolated using the 
explantation reexplantation method (48). Briefly, 2-mm3 muscle 
fragments were placed on the bottom of a Petri dish coated with 
a 1% gelatin solution containing human plasma. Cells were main-
tained in a replicative state for approximately 7 passages using a 
medium containing 15% serum and a cocktail of growth factors. 
During the experiments, all the myoblasts were maintained in 
SkGM-2 medium (Lonza). For estrogen starvation, cells were incu-
bated overnight in DMEM without phenol red supplemented with 
glutamine, human EGF (25 ng/ml), 10% charcoal/dextran-treated 
FBS (HyClone), gentamicine, and amphotericine B. The differen-
tiation medium was DMEM/F12 without phenol red supplement-
ed with 1% charcoal/dextran-treated horse serum. Treatment was 
with the following: 10 nM E2, 100 nM tamoxifen, 100 nM diarylpro-
pionitrile (DPN), and 100 nM 3β-diol.
The immortalization procedure consisted of transduction of myo-
blast cultures with 2 retroviral constructs produced in 293T packaging 
cells carrying the hTERT gene (provided by S. Bacchetti, McMaster 
University Hamilton, Ontario, Canada) and the CDK4-R24C variant 
(Addgene) plus the antibiotic resistance genes puromycin and hygro-
mycin. The transduced cells were selected by culture with puromycin 
and hygromycin.
Transient transfection was performed using JetPrime reagent 
(Polyplus) according to the manufacturer’s instructions. Cherry-DUX4 
was obtained by inserting DUX4 coding sequence in pLV-mCherry 
plasmid (Addgene) using BrsgI and SalI restriction enzyme sites in 
frame with mCherry-tag. AAV.CMV.DUX4-V5 construct was obtained 
by S.Q. Harper (The Ohio State University School of Medicine, Colum-
bus, Ohio, USA). All constructs were checked by sequencing.
Luciferase assays were performed by transient transfection 
of ERE3-tk-luc plasmid (M. Brown, Dana Farber/Harvard Cancer 
Center, Boston, Massachusetts, USA) in the presence or absence 
of pcDNA- FLAG-ERβ expression plasmid (Addgene) and using the 
Luciferase Assay Systems (Promega).
Cell proliferation was evaluated by CellTiter-Blue assay (Prome-
ga), a homogenous assay that measures the conversion of resazurin to 
resorufin by metabolically active cells. Briefly, 3 × 103 myoblasts/well 
were plated in a 96-multiwell plate and after 24 hours grown in starva-
tion medium for 16 hours. Then the cells were cultured in differentia-
tion medium in the absence or presence of E2. At different time points, 
CellTiter-Blue was added to the well, and after 2 hours, absorbance at 
570 and 600 nm were evaluated.
of healthy individuals, supporting their role as DUX4 targets in 
FSHD. Some authors report the lack of correlation between DUX4 
and PITX1 levels in FSHD myoblasts, questioning the existence 
of a direct link between these 2 genes (44). Our observations may 
reconcile these reports by showing a link during muscle differen-
tiation, but not in proliferating myoblasts. Consistently, Klooster 
et al. showed increased expression of PITX1 in FSHD myotubes, 
but not in FSHD myoblasts, compared with controls (44). How-
ever, the lower induction of PITX1 compared with TRIM43 and 
ZSCAN4 as well as its noncanonical DUX4-responsive elements 
(41) may suggest an indirect link and/or indicate the requirement 
of additional cofactor or cofactors for its transcription.
Estrogens antagonize DUX4 transcriptional activity at least 
in part by displacing it from chromatin. The ability of estrogen to 
relocalize cellular factors has already been reported, although the 
mechanism by which this ER activity occurs has not been elucidated 
(45). Data from our group exclude a direct binding between ERβ and 
DUX4 independently of cell growth conditions (data not shown), 
suggesting that ERβ may modulate cellular factors that in turn affect 
DUX4 nucleocytoplasmic shuttling during myoblast differentia-
tion. Although nuclear localization signals (NLS) have been recog-
nized in DUX4, only large deletion mutants of the protein alter its 
intracellular localization (46), suggesting that DUX4 cellular local-
ization is affected by other factors rather than from its specific NLS.
Our results are the first evidence, to our knowledge, of a pro-
gressive nuclear localization of DUX4 during the early steps of 
muscle differentiation. This phenomenon represents an addition-
al factor that contributes to modulating DUX4 activity and relat-
ed toxicity and suggests the possibility of interfering with DUX4 
pathogenicity by other approaches. Accordingly, some authors 
have shown that cytoplasmic localization of DUX4 is associated 
with the impairment of its function (46).
The existence of a link between estrogen and the FSHD is sup-
ported by the analysis of a limited number of FHD patients (Sup-
plemental Clinical Data). Indeed, this retrospective analysis sug-
gests that a rapid loss of estrogen levels and/or activity in female 
patients may contribute to worsening clinical symptoms, thus con-
tributing to disease variability, especially in those FSHD patients 
carrying a fragment size associated with incomplete penetrance 
of the disease. These conclusions are preliminary, and extensive 
clinical studies will be required to establish the beneficial effects 
of estrogens in FSHD patients.
Our data do not exclude that other adult hormones may 
affect FSHD. Particularly, given the equilibrium existing between 
female and male steroid hormones, namely estrogens and andro-
gens, it is not excluded that androgens may have a counterac-
tive function, worsening FSHD symptoms in males. However, 
the common knowledge of the positive activity of the androgen 
receptor toward the enlargement of skeletal muscle cells and 
fusion of myoblasts contrasts with the worse clinical symptoms 
associated with FSHD male patients.
Overall, these results point to estrogens as a potentially 
important factor affecting FSHD. Since effective pharmacologic 
treatments that improve patient symptoms and/or slow disease 
progression have not yet been reported (47), these data may be 
helpful in approaching therapy-decision strategies as well as in 
investigating novel hormone-based therapies for FSHD.
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nescence imaging system Alliance 2.7 (UVitec Cambridge) and quan-
tified by the software Alliance V_1607. Primary antibodies were as fol-
lows: α-DUX4 (Abcam, catalog 124699, clone E5.5), α–V5-tag (Santa 
Cruz Biotechnology Inc., catalog sc-58052), α-FLAG (Sigma-Aldrich, 
catalog A8592), α-ERβ (Genetex catalog 110607), α-ERα (Santa Cruz 
Biotechnology Inc., catalog sc-543) α-tubulin (Sigma-Aldrich, catalog 
T9026, clone DM-1A), α-H3 (Abcam, catalog AB1791), α-p21 (Santa 
Cruz Biotechnology Inc., catalog sc-6246), α-MDM2 (clone 2A10/
Ab1)(52), α-desmin (Santa Cruz Biotechnology Inc., catalog sc-58745, 
clone DE-R-11), α-actin (Sigma-Aldrich, A4700, clone AC40), and 
α-GAPDH (Millipore, catalog ABS16). IgG-HRP–conjugated second-
ary antibodies were as follows: α-rabbit (Santa Cruz Biotechnology 
Inc., catalog sc-2054) and α-mouse (Bio-Rad, catalog 1721011).
For subcellular fractionation, cells were resuspended in lysis buf-
fer A (10 mM HEPES, pH 7.9, 10 mM KCl, 1,5 mM MgCl2, 0,34 M sac-
charose, 10% glycerol, 0.5 mM EDTA, 0.5 mM EGTA, and 0.1% Tri-
ton X-100) added with protease inhibitors (Roche) and 0.5 mM PMSF 
(Sigma-Aldrich). After centrifugation, the supernatants corresponding 
to the cytoplasm fraction were further clarified by centrifugation at 
15000 g for 15 minutes. Nuclei pellets were washed once in buffer A 
and twice in PBS before resuspension in buffer B (3 mM EDTA, 0.5 
mM EGTA) added with protease inhibitor; these lysates were then 
incubated on ice for 30 minutes. After centrifugation at 2800 g for 4 
minutes at 4°C, the pellet obtained represents the chromatin-enriched 
fraction; this pellet was washed as indicated previously, resuspended 
in buffer B, and sonicated for 30 seconds at 50% amplitude.
ChIP. For the ChIP of overexpressed DUX4, 12 × 106 cells were 
grown in starvation medium for 16 hours and then transfected with 
Cherry-DUX4 plasmid and after 4 hours cultured in differentiation 
medium with or without E2. The crosslinking was performed after 24 
hours of growth in differentiation medium. For the ChIP of endogenous 
protein in the FSHD#4 cell line, we used 5 × 106 cells, and the cross-
linking was performed after 5 days of growth in differentiation medium. 
ChIP was performed according to Consalvi et al. (53). Briefly, chromatin 
was crosslinked with 1% formaldehyde (Sigma-Aldrich), and then gly-
cine was added to a final concentration of 0.125 M. After 5 minutes, cells 
were washed, scraped with PBS, and centrifuged. Then pellet samples 
were resuspended in nuclei lysis buffer (50 mM Tris-HCl, pH 8.1, 1% 
SDS, 10 mM EDTA) on ice for 30 minutes. Sonication was performed 
using a Bioruptor UCD-200 Sonicator (Diagenode). Chromatin extracts 
were immunoprecipitated overnight on a rotating platform at 4°C with 
the following antibodies: mix of α-DUX4 (Abcam, catalog 124699, clone 
E5.5) and α-mCherry (Thermo Fischer, catalog M11217) to immunopre-
cipitate overexpressed DUX4, α-DUX4 (Abcam, catalog 124699, clone 
E5.5) for the endogenous protein, and α-trimethyl-histone H3 (Lys4) 
(Millipore, catalog 07-473). No antibody was used as a negative control. 
Immunoprecipitated chromatin was conjugated with G Protein Magnet-
ic Beads (Invitrogen). After extensive washing, bound DNA fragments 
were eluted and analyzed by qPCR of ZSCAN4 (17) and MDM2 (54) pro-
moters, using SYBR Green Master Mix (Bioline).
Statistics. Methods used were 2-tailed Student’s t test for compari-
son of pairs and Kruskal-Wallis with Bonferroni’s correction for multi-
ple group comparison. A P value of less than 0.05 was considered sig-
nificant. The software used was Analyse-it (https://analyse-it.com/).
Study approval. All muscle biopsies were performed after informed 
consent of individuals. The clinical data derive from the routine follow-up 
of patients treated at the Centre Hospitalier, University of la Cote d’Azur, 
Immunofluorescence. 300 cells/mm2 were plated for each cell line. 
At different time points, cells were fixed in 80% acetone, blocked in 
5% BSA, then immunodecorated with primary antibodies α-desmin 
(Santa Cruz Biotechnology Inc., catalog sc-58745, clone DE-R-11) and 
α-MHC (clone MF20) (49). For V5 tag staining, cells were fixed in 4% 
formaldehyde, permeabilized with 0.05% Triton X-100, blocked with 
5% BSA, and then incubated with α-V5 antibody (Santa Cruz Biotech-
nology Inc.). Cytoplasm was counterstained with phalloidin (tebu-
bio). For endogenous DUX4, cells were fixed with 2% formaldehyde 
and permeabilized with 1% Triton X-100, then incubated with mixture 
of α-DUX4 (Abcam, catalog 124699, clone E5.5) 1:250 and α-MHC 
(clone MF20) overnight at 4°C (50). Secondary antibodies used were 
as follows: Cy3-conjugated AffiniPure donkey anti-mouse IgG  (Jack-
son ImmunoResearch, catalog 715165150) Cy2-conjugated Affin-
iPure donkey anti-mouse IgG (Jackson ImmunoResearch, catalog 
715225150), andCy2-conjugated AffiniPure donkey anti-rabbit IgG 
(Jackson ImmunoResearch, catalog 711225152). Slides were mounted 
with ProLong/DAPI (Life Technology) and examined by convention-
al epifluorescence microscope (Olympus BX51) and confocal system 
TCS-SP5 (Leica Microsystems). Images were captured by a SPOT RT3 
camera and elaborated by IAS software. All experiments were evalu-
ated by at least 3 independent observers, one of which was blinded.
RNA preparation and RT-PCR. RNA extraction was carried out 
with TRIzol reagent following the manufacturer’s instructions (Invi-
trogen). For quantitative reverse-transcription PCR (qRT-PCR), 500 
ng of RNA was reverse transcribed using the Gene Amp kit (Applied 
Biosystems) and subjected to PCR amplification using SYBR Green 
PCR Master Mix (Bioline) or specific probe/primers in the case of 
ESR2 and β-actin.
The following primers were used: forward hGAPDH 5′-GACAA-
GCTTCCCGTTCTCAG-3′, reverse hGAPDH 5′-GAGTCAACG-
GATTTGGTCGT-3′; β-actin preformulated assay (Applied Biosystems 
4310881E); forward hPITX1 5′-ACATGAGCATGAGGGAGGAG-3′, 
reverse hPITX1 5′-GTTACGCTCGCGCTTACG-3′; forward hAtrogin-1 
5′-CCTTTGTGCCTACAACTGAA-3′, reverse hAtrogin-1 5′-CTGC-
CCTTTGTCTGACAGAAT-3′; forward hTRIM43 5′-ACCCATCACT-
GGACTGGTGT, reverse hTRIM43 5′-CACATCCTCAAAGAG-
CCTGA; forward hZSCAN4 5′-TGGAAATCAAGTGGCAAAAAC, 
reverse hZSCAN4 5′-CTGCATGTGGACGTGGAC; forward DUX4 
5′-CCAAGGTACCAGCAGACC-3′, reverse DUX4 5′-TCCAGGAGAT-
GTAACTCTAATCCA-3′; probe ESR2 5′-/56-FAM/AAGTGCCGA/
ZEN/CGAGCAGCTG/3IABkFQ/-3′; forward ESR2 55′-GTGGGAAT-
GGTGAAGTGTG-3′, reverse ESR2 5′-ACTTCTCTTGGCCTTGCC-3′; 
and forward ESR1 5′-TCCTACCAGACCCTTCAGTGAAGCT-3′, 
reverse ESR1 5′-CATGTCGAAGATCTCCACCATGCC-3′.
Samples underwent 40 amplification cycles, monitored by an ABI 
Prism 7900 sequence detector (Applied Biosystems). All amplification 
reactions were conducted in triplicate and the average of threshold 
cycles was used to interpolate standard curves and calculate transcript 
amounts using the software SDS version 2.3 (Applied Biosystems) 
applying the Pfaffl model (51).
Western blot and isolation of cell fractions. For Western blot, cells 
were lyzed in RIPA buffer (50 mM Tris–Cl, pH 7.5, 150 mM NaCl, 
1% Nonidet P-40, 0.5% Na deoxycholate, 0.1% SDS, 1 mM EDTA). 
Proteins were resolved by SDS–PAGE and then transferred onto 
PVDF membranes (Millipore). Membranes were developed using the 
enhanced chemiluminescence kit (ECL Amersham) by the chemilumi-
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